Methods and compositions for regulating cell cycle progression
View Patent ↗In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5′ end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5″end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. In some embodiments, the method comprises introducing at least one iRNA that inhibits the expression of at least one miR-16 responsive gene selected from TABLE 5 into the mammalian cell.
1. A method of inhibiting proliferation of a mammalian cell comprising:
introducing into said cell an effective amount of small interfering RNA agents (iRNAs) that inhibit the expression of the miR-16 responsive genes represented by target sequences SEQ ID NOS:366, 368, 370, and 372;
wherein each of the miR-16 responsive genes comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3; and
wherein each of the iRNAs is at least 15 nucleotides in length and comprises a gene specific a nucleotide sequence that is substantially identical to the complement of a portion of an mRNA encoded by a target miR-16 responsive gene as represented by a gene target sequence selected from SEQ ID NOS:366, 368, 370, and 372.
2. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:1.
3. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:2.
4. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:4.
5. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:5.
6. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:6.
7. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:7.
8. The method of claim 1 , wherein the target miR-16 responsive gene comprises a nucleotide sequence that is complementary to eight contiguous nucleotides located within SEQ ID NO:3.
9. The method of claim 1 , wherein the mammalian cell is a cancer cell.
10. The method of claim 1 , wherein the mammalian cell is infected with a virus expressing a micro RNA species in the miR-16 family.
11. The method of claim 10 , wherein the mammalian cell is infected with kshv-miR-K12-6-5p.
12. The method of claim 1 , wherein at least one of the iRNA agents comprises at least one chemically modified nucleotide or non-nucleotide.
13. The method of claim 1 , wherein at least one of the iRNA agents comprises a dsRNA molecule comprising one nucleotide strand that is substantially identical to a portion of the mRNA encoded by at least one of the genes represented by a target sequence selected from SEQ ID NOS:366, 368, 370, and 372.
14. The method of claim 1 , wherein at least one of the iRNA agents comprises a ssRNA molecule comprising one nucleotide strand that is substantially complementary to a portion of the mRNA encoded by at least one of the genes represented by a target sequence selected from SEQ ID NOS:366, 368, 370, and 372.
15. The method of claim 1 , wherein at least one of the iRNA agents is at least one dsRNA molecule comprising a double-stranded region, wherein one strand of the double-stranded region is substantially identical to 15 to 25 consecutive nucleotides encoded by a gene represented by a target sequence selected from SEQ ID NOS:366, 368, 370, and 372 and the second strand is substantially complementary to the first, and wherein at least one end of the dsRNA has an overhang of 1 to 4 nucleotides.
16. The method of claim 1 , wherein at least one of the iRNA agents comprises at least one dsRNA molecule comprising at least one of SEQ ID NO:272-277, SEQ NO:284-289, SEQ ID NO:290-295, SEQ ID NO:248-253, SEQ ID NO:344-349, SEQ ID NO:350-355, SEQ ID NO:356-361.
17. The method of claim 9 , wherein the cancer cell is an miR-16 mediated cancer cell.
18. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO: 1, wherein position 1 represents the 5′ end of SEQ ID NO: 1.
19. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO: 2, wherein position 1 represents the 5′ end of SEQ ID NO:2.
20. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:4, wherein position 1 represents the 5′ end of SEQ ID NO:4.
21. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:5, wherein position 1 represents the 5′ end of SEQ ID NO:5.
22. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:6, wherein position 1 represents the 5′ end of SEQ ID NO:6.
23. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:7, wherein position 1 represents the 5′ end of SEQ ID NO:7.